litlas
ログインアカウント作成

Bruce D. Cheson

1976–2024 年に発表

別表記
BRUCE D. CHESON
159
論文数
55,673
被引用数
102
h 指数
158
i10 指数

被引用数

Bruce D. Cheson の年別被引用数1948 年: 被引用 5 件1977 年: 被引用 5 件1978 年: 被引用 8 件1979 年: 被引用 4 件1980 年: 被引用 4 件1981 年: 被引用 4 件1982 年: 被引用 3 件1983 年: 被引用 3 件1984 年: 被引用 4 件1985 年: 被引用 3 件1986 年: 被引用 3 件1987 年: 被引用 4 件1988 年: 被引用 2 件1989 年: 被引用 7 件1990 年: 被引用 19 件1991 年: 被引用 26 件1992 年: 被引用 35 件1993 年: 被引用 35 件1994 年: 被引用 44 件1995 年: 被引用 48 件1996 年: 被引用 47 件1997 年: 被引用 51 件1998 年: 被引用 62 件1999 年: 被引用 77 件2000 年: 被引用 92 件2001 年: 被引用 114 件2002 年: 被引用 179 件2003 年: 被引用 231 件2004 年: 被引用 171 件2005 年: 被引用 198 件2006 年: 被引用 247 件2007 年: 被引用 312 件2008 年: 被引用 313 件2009 年: 被引用 358 件2010 年: 被引用 383 件2011 年: 被引用 363 件2012 年: 被引用 372 件2013 年: 被引用 339 件2014 年: 被引用 397 件2015 年: 被引用 465 件2016 年: 被引用 405 件2017 年: 被引用 440 件2018 年: 被引用 434 件2019 年: 被引用 1,390 件2020 年: 被引用 1,489 件2021 年: 被引用 1,356 件2022 年: 被引用 1,047 件2023 年: 被引用 704 件2024 年: 被引用 1,080 件2025 年: 被引用 450 件2026 年: 被引用 13 件1949〜1976 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,296 件、この内訳の 27%ドイツ: 引用元論文 1,410 件、この内訳の 7.2%イタリア: 引用元論文 1,389 件、この内訳の 7.1%イギリス: 引用元論文 1,288 件、この内訳の 6.6%フランス: 引用元論文 1,260 件、この内訳の 6.4%中国: 引用元論文 907 件、この内訳の 4.6%スペイン: 引用元論文 779 件、この内訳の 4%カナダ: 引用元論文 711 件、この内訳の 3.6%スイス: 引用元論文 605 件、この内訳の 3.1%オーストラリア: 引用元論文 574 件、この内訳の 2.9%オランダ: 引用元論文 538 件、この内訳の 2.7%日本: 引用元論文 406 件、この内訳の 2.1%
0%27%その他 22.7%

機関

分野

  • Medicine84.2%
  • Biochemistry, Genetics and Molecular Biology10.4%
  • Immunology and Microbiology2.9%
  • Engineering0.4%
  • Computer Science0.4%
  • Chemistry0.3%
  • その他1.4%

トピック

  • Lymphoma Diagnosis and Treatment15.1%
  • Chronic Lymphocytic Leukemia Research9.1%
  • Acute Myeloid Leukemia Research5.4%
  • CAR-T cell therapy research4.8%
  • CNS Lymphoma Diagnosis and Treatment3.4%
  • Viral-associated cancers and disorders3%
  • その他59.2%

共著者

全論文

検索で開く
  1. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

    著者: Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington, Franco Cavalli, Lawrence H. Schwartz, Emanuele Zucca, Tim Lister - Journal of Clinical Oncology 2014 被引用: 5,552

  2. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    著者: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 被引用: 1,689

  3. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    著者: Bruce D. Cheson, John M. Bennett, Kenneth J. Kopecky, Thomas Büchner, Cheryl L. Willman, Elihu H. Estey, Charles A. Schiffer, Hartmut Doehner, Martin S. Tallman, Tim Lister, Francesco Lo‐Coco, Roel Willemze, Andrea Biondi, Wolfgang Hiddemann, Richard A. Larson, Bob Löwenberg, Miguel Á. Sanz, David R. Head, R Ohno, Clara D. Bloomfield - Journal of Clinical Oncology 2003 被引用: 2,662

  4. Revised Response Criteria for Malignant Lymphoma

    著者: Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin Dreyling, Kensei Tobinai, Julie M. Vose, Joseph M. Connors, Massimo Federico, Volker Diehl - Journal of Clinical Oncology 2007 被引用: 4,448

  5. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    著者: Bruce D. Cheson - Blood 2006 被引用: 1,588

  6. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

    著者: Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu, Michel Meignan, Martin Hutchings, Stefan Müeller, Lawrence H. Schwartz, Emanuele Zucca, Richard I. Fisher, Judith Trotman, Otto S. Hoekstra, Rodney J. Hicks, Michael O’Doherty, Roland Hustinx, Alberto Biggi, Bruce D. Cheson - Journal of Clinical Oncology 2014 被引用: 1,648

  7. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    著者: Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi Pederson, Mei‐Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner‐Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha Reddy, Jane N. Winter, Julie Chang, Ajay K. Gopal, Amy Chadburn, Susan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schöder, Andrew D. Zelenetz, John P. Leonard - Journal of Clinical Oncology 2019 被引用: 423

  8. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    著者: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 被引用: 1,684

  9. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    著者: Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen - Journal of Clinical Oncology 2012 被引用: 1,520

  10. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

    著者: Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian T. Hill, Christina Howlett, Alan P Skarbnik, Bruce D. Cheson, Clive S. Zent, Jeffrey J. Pu, Pavel Kiselev, André Goy, David F. Claxton, Krista M. Isaac, Kaitlin Kennard, Colleen Timlin, Daniel J. Landsburg, Allison Winter, Sunita D. Nasta, Spencer Henick Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul M. Barr, Chaitra S. Ujjani - Haematologica 2018 被引用: 452

  11. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    著者: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Kanti R. Rai, Thomas J. Kipps - Blood 2008 被引用: 3,193

  12. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

    著者: Bruce D. Cheson, Stephen M. Ansell, Larry Schwartz, Leo I. Gordon, Ranjana H. Advani, Heather A. Jacene, Axel Hoos, Sally F. Barrington, Philippe Armand - Blood 2016 被引用: 506

  13. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

    著者: Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Steven Coutré, Jennifer A. Woyach, John C. Byrd - The Lancet Oncology 2017 被引用: 378

  14. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

    著者: Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. Chen, Sarit Assouline, Bruce D. Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lü, Elicia Penuel, Jamie Hirata, Michael Wenger, Yu-Waye Chu, Jeff P. Sharman - The Lancet Haematology 2019 被引用: 249

  15. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    著者: Bruce D. Cheson, Sandra J. Horning, B Coiffier, Margaret A. Shipp, Richard I. Fisher, Joseph M. Connors, Tim Lister, Julie M. Vose, Antonio J Grillo-López, Anton Hagenbeek, Fernando Cabanillas, Donald Klippensten, Wolfgang Hiddemann, Ronald A. Castellino, Nancy L. Harris, Jamés O. Armitage, William Carter, Richard T. Hoppe, George P. Canellos - Journal of Clinical Oncology 1999 被引用: 3,490

  16. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    著者: Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer - Journal of Clinical Oncology 2019 被引用: 221

  17. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

    著者: Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng S. Quah, Rakesh Kumar Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps - Haematologica 2021 被引用: 108

  18. Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

    著者: James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin‐Ho Jung, Megan O. Nakashima, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan - Journal of Clinical Oncology 2013 被引用: 499

  19. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

    著者: Gary J. Kelloff, John M. Hoffman, Bruce E. Johnson, Howard I. Scher, Barry A. Siegel, Edward Y. Cheng, Bruce D. Cheson, Joyce O’Shaughnessy, Kathryn Z. Guyton, David A. Mankoff, Lalitha Shankar, Steven M. Larson, Caroline C. Sigman, Richard L. Schilsky, Daniel C. Sullivan - Clinical Cancer Research 2005 被引用: 669

  20. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

    著者: Matthias Pfeifer, Bing Zheng, Tabea Erdmann, Hartmut Koeppen, Ronald McCord, Michael Grau, Annette M. Staiger, Akiko Chai, Thomas Sandmann, Hannelore Madle, Bernd Dörken, Y-W Chu, A I Chen, Dan I. Lebovic, Gilles Salles, M. S. Czuczman, Maria Corinna Palanca-Wessels, Oliver W. Press, Ranjana H. Advani, Franck Morschhauser, Bruce D. Cheson, Peter Lenz, German Ott, Andrew G. Polson, Kirsten Mundt, Georg Lenz - Leukemia 2015 被引用: 152

  21. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

    著者: Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun Ju Lee, Ranjana J Advani, Beth Christian, Catherine Diefenbach, Tatyana Feldman, Stephen M. Ansell - The Lancet Haematology 2020 被引用: 96

  22. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

    著者: Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopińska‐Posłuszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech‐Marańda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chávez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O’Connor, Michael Weiss, Pier Luigi Zinzani - Journal of Clinical Oncology 2021 被引用: 161

  23. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

    著者: Laurie H. Sehn, Neil Chua, Jiřı́ Mayer, Gregg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver W. Press, Gilles Salles, John G. Gribben, Anne Lennard, Pieternella J. Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle‐Rowson, Bruce D. Cheson - The Lancet Oncology 2016 被引用: 343

  24. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

    著者: Malik E. Juweid, Sigrid Stroobants, Otto S. Hoekstra, Felix M. Mottaghy, Markus Dietlein, Ali Guermazi, Gregory A. Wiseman, Lale Kostakoğlu, Klemens Scheidhauer, Andreas K. Buck, Ralph Naumann, Karoline Spaepen, Rodney J. Hicks, Wolfgang Weber, Sven N. Reske, Markus Schwaiger, Lawrence H. Schwartz, Josée M. Zijlstra, Barry A. Siegel, Bruce D. Cheson - Journal of Clinical Oncology 2007 被引用: 1,336